# Adult Pneumonia Guideline (Community and Hospital-acquired)

Document Registration Number: HNEH CPG xxxx

| Sites where CPG applies | Acute Networks Hospitals
| | Primary & Community Networks |
|-------------------------|---------------------------------
| Target Clinical Audience | This CPG is applicable to adults
| | All clinicians who treat adult pneumonia
| | Pharmacists |
| Applicability | *(Please indicate with a X in the appropriate box)*
| | Neonate – less than 29 days: N
| | Children up to 16 years*: N
| | Adult (18 years and over): Y
| | All of the above: □ |
| Summary | This document describes expert recommendations relating to management of CAP in facilities managed by Hunter New England Health Service. |
| Keywords | Pneumonia, Legionella, influenza, antibiotic stewardship |
| Replaces existing clinical practice guideline or policy? | Yes |
| Registration Numbers of Superseded Documents | HNEH CPG 09_06 (CAP CPG)
| | HNEH CPG 08_05 (HAP CPG) |
| Related documents (Policies, Australian Standards, Codes of Conduct, legislation etc) | Detail main parent documents that informs this CPG |
| | • Therapeutic Guidelines: Antibiotic, Therapeutic Guidelines, Melbourne, Victoria 2010 |
| Clinical Network/stream leader responsible for CPG | |
| Contact Person/Position Responsible | |
| Contact Details | |
| Review Due Date: | July 2012 |
| Date authorised by Area Quality Use of medicines | |
| Date authorised by Area Clinical Network/stream | |
| Date Authorised by HNE Clinical Quality and Patient Safety Committee | |
| Trim Number | |
Glossary

<table>
<thead>
<tr>
<th>AFB</th>
<th>acid fast bacilli – e.g. <em>Mycobacteria</em> species such as tuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAL</td>
<td>Broncho-alveolar lavage</td>
</tr>
<tr>
<td>CAP</td>
<td>community-acquired pneumonia</td>
</tr>
<tr>
<td>CAPAC</td>
<td>Community Acute Post-Acute Care (CAPAC)- hospital in the home care team that operates from several HNE Centres</td>
</tr>
<tr>
<td>CI</td>
<td>Contraindication</td>
</tr>
<tr>
<td>CORB</td>
<td>acronym for the severity scoring system (Confusion, Oxygenation, Respiratory rate, Blood pressure) in use for CAP assessment in adults</td>
</tr>
<tr>
<td>HAP</td>
<td>Healthcare (hospital)-associated pneumonia</td>
</tr>
<tr>
<td>HAPS</td>
<td>Hunter Area Pathology Service</td>
</tr>
<tr>
<td>HDU</td>
<td>High Dependency Unit</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LP1</td>
<td><em>Legionella pneumophila</em> serogroup 1, the commonest cause of legionellosis</td>
</tr>
<tr>
<td>MRSA</td>
<td>methicillin-resistant <em>Staphylococcus aureus</em></td>
</tr>
<tr>
<td>NPA</td>
<td>nasopharyngeal aspirate</td>
</tr>
<tr>
<td>P2 mask</td>
<td>particulate filter mask used for protection against airborne fine particle infected aerosols</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction – a test that amplifies very small quantities of DNA or RNA from a pathogen within a sample so that detection (diagnosis) can occur</td>
</tr>
<tr>
<td>PPE</td>
<td>personal protective equipment (e.g. mask, gown, gloves, eye protection)</td>
</tr>
<tr>
<td>RSV</td>
<td>Respiratory syncytial virus – the commonest cause of bronchiolitis in infants. Also a cause of pneumonia in adults</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
</tbody>
</table>

*The current CAP/HAP business card-sized summary is available from Acute Networks Pharmacy Departments.*

**IMPORTANT NOTE:**

**Clarithromycin potential interactions:** Clarithromycin inhibits the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). This interaction may result in myopathy and rhabdomyolysis, particularly in patients with renal insufficiency or those who are concurrently taking medications associated with myopathy.

Also avoid clarithromycin with colchicine as a potentially life threatening reaction may occur.
1.0 COMMUNITY-ACQUIRED PNEUMONIA (CAP) GUIDELINE

Overview (CAP)

Optimal management of CAP improves patient outcome. Important aspects include:

- Assessment to identify unusual risk exposures
- Severity assessment using the CORB (Confusion, Oxygenation, Respiratory rate, Blood pressure) scoring at presentation (use the worst parameters recorded for each during the ED stay or first 24 hrs) to identify patients with severe pneumonia. CORB can also be used to assess patients with influenza-like illness.
- Investigation of patients with severe pneumonia to demonstrate an infective cause that enables later targeting of antibiotic therapy
- Influenza testing of admitted CAP cases during May-November period. Pending influenza results, start antiviral treatment for patients with recent onset of symptoms (< 72hrs) or with severe disease (at any time following symptom onset)
- Broad spectrum empiric antibiotic treatment for all severe cases to ensure that atypical causes such as Legionella and Gram negative pneumonia are treated from the outset.
- Cases of severe pneumonia due to strains of community MRSA are becoming more frequent in Northern NSW. It is important to give consideration to this diagnosis and adjust empiric treatment if pneumonia due to Staph. aureus is considered possible.

Clinical Assessment

In view of the danger to healthcare staff posed by transmissible respiratory pathogens such as influenza, it is essential that Droplet Additional Infection Control Precautions are followed (alcohol hand rub, don personal protective equipment upon room entry- surgical mask and protective eye wear) for all initial clinical interactions and specimen collection. Collection of NPA requires donning of P2 mask, protective eye wear, long sleeve impervious gown and gloves in that order- seek advice if uncertain about this PPE process.

i) Is it 'severe' community-acquired pneumonia?

This is the most important determination. Presence of two or more CORB criteria is sufficient to indicate presumptive severe pneumonia (quite aside from whether the patient has or will be admitted to ICU) and indicates that broad-spectrum empiric antibiotics are required from the start. The therapy is selected to particularly provide adequate cover for:
- Streptococcus pneumoniae (i.e. benzylpenicillin )
- Legionella (azithromycin)
- aerobic Gram negatives such as Klebsiella species (gentamicin)
- Staph. aureus (gentamicin or add vancomycin to cover community methicillin-resistant Staph. aureus (MRSA) if suspicion high- see Sputum examination below).

An assessment of the patient by the ICU team is advisable in all severe cases.

ii) Admission criteria

Patients who have no preceding cardiac and respiratory disease and who present with mild or moderate pneumonia can usually be managed as an outpatient. All of these patients need review the next day by their General Practitioner (GP) or the Community Acute Post-Acute Care (CAPAC) team and later review by their GP.

Patients with chronic cardiac, respiratory or neurological problems or who are immunosuppressed, are at higher risk of complications and should be considered for admission. All immunocompromised patients with CAP should be discussed with a consultant upon admission and before discharge (if going home from ED).
Patients who have failed to respond to a reasonable course of oral antibiotics, should be considered for admission and parenteral therapy. Clinical judgement and the patient’s social circumstances are important factors in this decision.

iii) Diagnostic considerations
Relevant considerations include:
- Season (winter- pneumococcus, Respiratory syncytial virus (RSV) (even in adults; onset of season often in May), Influenza (June to November usually)
- Comorbid conditions Chronic Airflow Limitation (Haemophilus), other lung disease (complex)
- exposure to birds (psittacosis), potting mix or gardening (Legionella longbeachae), animals/rural (Coxiella burnetii - Q Fever)
- pregnancy- throughout pregnancy and puerperum, women are at risk from severe influenza
- immune-competency: in particular, cell-mediated immune deficiency (eg. AIDS, post organ transplant patient) raises the possibility of Pneumocystis or tuberculosis.

The clinical and radiological presentation seldom permits prediction of the aetiology. Occurrence of abscess(es) indicates a pyogenic cause (e.g. Staph. aureus, β-haemolytic strains of streptococci, anaerobic organisms, Klebsiella species.)

Presence of sudden onset rigors, pleuritic pain, purulent sputum with lobar consolidation has a sensitivity of 30% and specificity of 91% for pneumococcal pneumonia.

Presence of an asthma-like presentation in adult with prominent wheeze is suggestive of primary RSV pneumonia.

Investigation of CAP

i) Routine investigations (All patients in the Emergency Department):
- Two blood culture sets (20mLs in two bottles for adult/adolescent). Collect with correct asepsis from different venepuncture sites. Collect prior to antibiotics.
- Sputum (if possible) microscopy and culture (an acceptable specimen contains >25 neutrophils and <10 epithelial cells per high power field).

ii) Additional investigations for patients who require admission
In the ED:
- Serum for Mycoplasma IgM (acute-phase)
In the ED or on the ward:
- May to November- Influenza PCR on nose and throat swab sample (NPA is an acceptable alternative from infants).
- Consider urine for Legionella LP1 antigen.

iii) Additional investigations for patients with severe CAP (see Appendix A- Checklist for Severe CAP in ICU)
- Sputum Legionella PCR.
- Urine for Legionella (LP1) and Streptococcus pneumoniae antigens (can be collected up to 1 week post presentation).
- NPA or BAL for respiratory virus detection (in ICU), especially if initial influenza testing is negative (see below).

iv) Additional notes:
Legionella detection
Detection is by polymerase chain reaction (PCR) nucleic acid detection (must be specifically requested from HAPS) AND urinary antigen detection for Legionella pneumophila serogroup 1 antigen. See also Acute Serology, next section below.
**Sputum gram stain and culture**

If the patient can produce a well-expectorated specimen (not salivary, >25 neutrophils and <10 epithelial cells per high power field), presence of typical organisms suggestive of either *Strep. pneumoniae* (pneumococcus -Gram positive diplococci) or *Haemophilus* (small Gram negative rods) had the following sensitivity and specificity in one of many studies:

<table>
<thead>
<tr>
<th></th>
<th><em>S. pneumoniae</em> (presumptive)</th>
<th><em>Haemophilus</em> (presumptive)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>56%</td>
<td>82%</td>
</tr>
<tr>
<td>Specificity</td>
<td>97%</td>
<td>99%</td>
</tr>
</tbody>
</table>

Presence of predominant Gram positive cocci in clusters, i.e. Staphylococci and profuse white cells indicates probable *Staph. aureus* pneumonia. In this case pre-treatment blood cultures are often positive within 24hrs.

**Acute Serology**

Acute serum for *Mycoplasma* IgM is usually tested twice a week in the laboratory. For other causes, an acute serum is important but it may be held untested (as it would normally be negative) until a convalescent serum is also received in the laboratory (at least 3 weeks after onset of illness). Note that delayed seroconversion is the rule in *Legionella* infection. If *L. longbeachae* is suspected, then request this specifically as routine *Legionella* serology seldom detects this.

**Mycobacterial Ziehl-Nielsen (acid fast bacilli- AFB) stain and culture**

Should be considered in the appropriate clinical circumstance, and is a particular concern in the elderly, immunosuppressed and immigrants from high prevalence countries.

**Pleural fluid studies**

Presence of significant amount of pleural fluid should prompt aspiration for microscopy, biochemistry and culture (+/- AFB examination). The presence of a complicated parapneumonic effusion dictates urgent drainage. Where TB is a possibility, pleural biopsy with culture is optimal for detection.

**Virus detection**

Nasopharyngeal aspirate or bronchial lavage/washing best in ICU case.

Request “RSV only” for a same day rapid test.

Request “respiratory virus screen” for rapid testing locally by immunofluorescence for influenza, parainfluenza, adenovirus, RSV & metapneumovirus.

(PCR for an extended range of respiratory viruses is more sensitive but is a sendaway test with a one week turnaround)

During influenza season (Late May to November), send combined nose/throat swab & request Influenza PCR (done second daily locally).

ICU experience in 2009 and 2010 showed that repeat influenza PCR testing from a nasopharyngeal aspirate or lower tract sample was of value in confirming a diagnosis in patients with initial negative results from nose/throat.
CAP Empirical treatment (see right)

During the influenza season, all admitted cases of CAP with recent onset of symptoms (< 72hrs) should also be considered for oral oseltamivir treatment after collection of influenza investigations (nose/throat swab usually). In confirmed cases, continue antiviral treatment for 5 days and consider cessation of antimicrobials. ICU patients may need longer treatment.

The adult CAP pathway (see Appendix) is available on SALMAT.

Potential for clarithromycin interactions

Clarithromycin inhibits the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). This interaction may result in myopathy and rhabdomyolysis, particularly in patients with renal insufficiency or those who are concurrently taking medications associated with myopathy. Also avoid clarithromycin with colchicine as a potentially life threatening reaction may occur.

Review clinical & microbiology status at 48 hours

Change to directed (targeted) therapy against a demonstrated pathogen as soon as possible. In particular it may be possible to cease gentamicin or switch to an oral option. See Therapeutic Guidelines:Antibiotic for specific recommendations for a demonstrated bacteriological cause of CAP.

Duration of therapy

The usual duration of antimicrobial therapy for non-severe CAP is 5-7 days. Early cessation is recommended if viral pneumonia is proven.

Possible causes of CAP treatment failure

<table>
<thead>
<tr>
<th>Reason for failure</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incorrect diagnosis</td>
<td>pulmonary embolism, pulmonary oedema, pulmonary eosinophilia, Wegener’s granulomatosis, drug allergy, lung cancer</td>
</tr>
<tr>
<td>Resistant organism/infection</td>
<td>Mycoplasma pneumoniae, Chlamydia psittaci, Coxiella burnettii, Staphylococcus aureus, β-lactamase-producing Haemophilus influenzae (unusual) viral infection pulmonary tuberculosis Pneumocystis carinii</td>
</tr>
<tr>
<td>Inadequate drug, dose or route of administration</td>
<td>oral erythromycin for Legionella infection (inadequate tissue levels achieved) azithromycin is inactive against Coxiella burnettii (Q Fever)</td>
</tr>
<tr>
<td>Complication</td>
<td>empyaema, abscess, pulmonary embolism, fever related to drug therapy</td>
</tr>
<tr>
<td>Underlying disease</td>
<td>lung cancer, cardiac failure, immunodeficiency</td>
</tr>
</tbody>
</table>
2.0 HOSPITAL-ACQUIRED PNEUMONIA (HAP) GUIDELINE

Overview (HAP)

Hospital-acquired pneumonia (HAP) is pneumonia manifesting > 48 hrs after hospital admission. Early HAP (within 5 d admission) is often due to the same organisms (bacteria and viruses) that cause community-acquired pneumonia. Late HAP may be caused by community or hospital pathogens, the latter more likely in ventilated ICU patients.

Optimal management of HAP requires consideration of the following elements:
- Appropriate investigation prior to treatment
- Appropriate empiric antibiotic therapy
- Review of the patient’s clinical and microbiological status at 48 hrs to optimise treatment and target treatment at a demonstrated pathogen(s)
- Minimising the duration of treatment to reduce antibiotic exposure

Investigation of HAP

Collect sputum or BAL for bacterial culture, blood cultures (2 sets) prior to antibiotic therapy, Legionella urinary antigen, nose/throat swabs for influenza PCR / viral culture should also be considered. Non-infective causes for consolidation should always be considered.

Empirical HAP treatment (see right)

Modify in the light of organisms known to be colonising the patient.

Gentamicin is relied upon for initial therapy in pneumonia because it penetrates well to the lung and has a much broader spectrum against most Gram negatives than does cefotaxime or ceftriaxone. It is also more rapidly bactericidal than β-lactam agents. It has demonstrated safety in patients with severe sepsis.

Review clinical & microbiology status at 48 hours

Options at that point include:
- ceasing therapy (if an alternative cause for consolidation is likely)
- ceasing gentamicin and continuing β-lactam (Gram negative infection excluded by negative cultures (blood / sputum)
- targeting therapy against demonstrated pathogen(s)
- switch to an oral option at that point (patient improving)
- obtaining Infectious Diseases advice in the event of progressing pneumonia
Duration of therapy

For non-ICU or high dependency patients, 5-7 days is sufficient.

For Intensive care cases, 7 days is the usual duration with longer (up to 14 days) therapy required for proven pseudomonal infection. Short course therapy (3 days) can be considered in circumstances where either an alternative diagnosis for consolidation has been documented and/or patient response to initial antibiotics was rapid.
# Appendix 1: Adult CAP Pathway (2 pages back-to-back)

## Adult Community Acquired Pneumonia

### Adult CAP Pathway

**Signs/Symptoms**

<table>
<thead>
<tr>
<th></th>
<th>Score OHE point for each feature present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>new onset or worsening of existing state if cognitive impairment present</td>
</tr>
<tr>
<td>Oxygen</td>
<td>( \text{PaO}_2 \leq 60\text{mmHg or } \text{O}_2 \text{ sat} \leq 90% )</td>
</tr>
<tr>
<td>Respiratory Rate</td>
<td>( \geq 30\text{min} )</td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>systolic BP &lt; 90 mmHg or diastolic ( \leq 60 ) mmHg</td>
</tr>
</tbody>
</table>

**Total Score**

### Empiric Antibiotic Therapy

- **First line**
  - MILD score = 0
    - Amoxicillin 1 g oral 8-hrly, 5-7 days
  - MODERATE score = 1
    - Benzylpenicillin 1.2 g IV 6-hrly TOGETHER WITH EITHER Doxycycline 100 mg oral 12-hrly, 7 days OR Clarithromycin 500 mg oral 12-hrly, 7 days
  - SEVERE/ICU/HDU score = 2 or more
    - Benzylpenicillin 1.2 g IV 4-hrly AND Ceftriaxone daily IV SEE overleaf for PBS prescribing information

- **Penicillin allergy**
  - Clarithromycin 250 mg oral 12-hrly, 5-7 days
  - Ceftriaxone 1 g IV daily, 7 days TOGETHER WITH EITHER Doxycycline 100 mg oral 12-hrly, 7 days OR Clarithromycin 500 mg oral 12-hrly, 7 days
  - SEE overleaf for PBS prescribing information

**Notes**

- MRSA pneumonia has high mortality: always consult Infectious Diseases
  - Add vancomycin if staph pneumonia possible (CXR or sputum Gram stain); CrCl > 60 mL/min: 15 g IV 12-hrly (maximum infusion rate 10 mg/min). See Therapeutic Guidelines: Antibiotic on CIAP for doses in patients with renal failure.

**Investigations in ED**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FBC, UEC, BSL, sputum culture (if possible)</td>
<td>Add: Blood culture (2 separate sets). Mycoplasma IgM (acute serum). May-November: viral throat/nose swabs for influenza PCR. Severe (ICU): add Legionella sputum PCR, urine antigens for Legionella and Strep. pneumoniae, serum for Q fever IgM. Extended respiratory virus PCR on nose/throat sample or BAL.</td>
</tr>
</tbody>
</table>

**Home treatment usually feasible**

- Mild or moderate CAP
- Good social support
- No unstable co-morbidities
- LIAISE WITH CAPAC OR GP PRIOR TO DISCHARGE

**Hospital admission usually required**

- Moderate or severe CAP
- Failure to respond to oral therapy as outpatient
- Immunocompromised patients (see consultant advice)
- ICU consultation advised (i.e. severe CAP or respiratory failure)

---

**Doctor Name (print)________________________ Doctor Name (Signature)________________________**

**Date:__________ Time:__________**

---

**PLEASE RETAIN in Patient File**
Adult Community-Acquired Pneumonia (CAP): Key Points

Correct identification of severe pneumonia enables appropriate investigation, early broad spectrum antibiotic therapy (that includes Legionella cover) and necessary respiratory support.

Immunocompetency: patients with chronic cardiac, respiratory or neurological problems or who are immunosuppressed, are at higher risk of complications and should be considered for admission and should be discussed with the consultant prior to discharge if going home from ED.

Serology: Acute serum sent for Mycoplasma IgM. Acute serum will be stored by Virology for later testing. Testing for other requested causes will proceed once a convalescent sample (>3 wks after onset) is received.

PCR diagnosis of respiratory viruses: The combined nose/throat sample for flu PCR has a special collection procedure (see below). Request extended respiratory virus PCR on severe CAP ICU cases.

Atypical pathogens: Legionella diagnosis has important public health implications. Additional tests for Legionella are required particularly if renal failure and/or GI symptoms present.

Antibiotic administration within 4 hours of arrival is associated with decreased mortality.

Streptococcus pneumoniae remains the most important cause of CAP in our community. Amoxicillin and benzylpenicillin retain efficacy in CAP due to pneumococcal strains with raised minimal inhibitory concentration to betalactams. Benzylpenicillin is also active against most (80%) of Haemophilus influenzae.

Azithromycin is retained for severe CAP in order to provide cover against Legionella, pertussis and other atypical pathogens. It is NOT active against Coxiella burnetii (Q fever agent).

Clarithromycin: PBS listing is for 250mg tablets (14) + 1 repeat (note the 500mg tablets are NOT on the PBS).

MRSA strains with enhanced potential for causing pneumonia circulate in the community. Adult vancomycin dosing recommendations have changed recently (Therapeutic Guidelines: Antibiotic, Edition 14).

<table>
<thead>
<tr>
<th>Gentamicin</th>
<th>Recommended gentamicin starting doses:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Age</td>
<td>Initial dose</td>
</tr>
<tr>
<td>10 – 29 years</td>
<td>6 mg/kg up to 560 mg</td>
</tr>
<tr>
<td>30 – 60 years</td>
<td>5 mg/kg up to 480 mg</td>
</tr>
<tr>
<td>&gt; 60 years</td>
<td>4 mg/kg up to 400 mg</td>
</tr>
<tr>
<td>Septic shock</td>
<td>7 mg/kg up to 640 mg</td>
</tr>
</tbody>
</table>

Adult doses: these should be rounded to the nearest 40mg increment

<table>
<thead>
<tr>
<th>Gentamicin</th>
<th>Recommended gentamicin dosing interval:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine clearance (mL/min)</td>
<td>Dosing interval</td>
</tr>
<tr>
<td>&gt; 80</td>
<td>24 hrs</td>
</tr>
<tr>
<td>40 – 60</td>
<td>36 hrs</td>
</tr>
<tr>
<td>30 – 40</td>
<td>48 hrs</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>Give initial dose only and seek expert advice</td>
</tr>
</tbody>
</table>

Collection procedure: nasal/throat swab for influenza or respiratory virus PCR

Equipment
- Viral swabs (green top viral transport swab) x 2 (must be correct swab type)
- Wooden or plastic disposable tongue depressor
- Personal protective equipment (surgical mask, eye goggles)
- Alcohol based hand rub (ABHR)

Procedure
1. Explain the procedure to the patient.
2. Clean hands with alcohol based hand rub (ABHR) and put on PPE (protective glasses and mask)
3. Sample nose by gently rubbing the medial nasal mucosa on both sides while rotating the swab; then insert swab into transport medium.
4. Sample both tonsils and the posterior oropharynx with the other swab. Avoid touching the swab on the tongue or other parts of the mouth; insert swab into transport medium.
5. Forward the labelled specimens to Pathology service as soon as possible.
6. Discard PPE and clean hands with ABHR or wash hands.

Appendix 2:

**Investigation Checklist for Severe Community Acquired Pneumonia Cases Admitted to Intensive Care Units**

<table>
<thead>
<tr>
<th>Date collected</th>
<th>Investigation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-treatment blood cultures – at least two sets (20mLs each set for adult, 3-5mL for child/infant)</td>
</tr>
<tr>
<td></td>
<td>Serum for <em>Mycoplasma</em> IgM - this sera is automatically for later testing</td>
</tr>
<tr>
<td></td>
<td>EDTA blood for <em>Coxiella burnetii</em> (Q fever) PCR (adults)</td>
</tr>
<tr>
<td></td>
<td>Throat and nose viral swabs for influenza PCR (May-Nov only)</td>
</tr>
<tr>
<td></td>
<td>Pre-treatment sputum for routine culture and <em>Legionella</em> culture &amp; PCR (adults only)</td>
</tr>
<tr>
<td></td>
<td>Urine for <em>Streptococcus pneumoniae</em> and <em>Legionella pneumophila</em> type 1 antigen detection</td>
</tr>
<tr>
<td></td>
<td>NPA/BAL for respiratory virus detection <em>(send if initial influenza PCR and bacterial cultures are negative at 24hrs)</em></td>
</tr>
</tbody>
</table>

**Notes:**
- Sputum sample is also suitable for *Legionella* PCR and respiratory virus detection.
- ICU experience in 2009 and 2010 shows that repeat influenza testing from a lower tract sample is of value in confirming a diagnosis in patients with initial negative results from nose/throat.
- Tests as above must be requested specifically on pathology request form. Additional serological requests can be made on sera held in the laboratory by referring back to the relevant lab number.
3.0 IMPLEMENTATION PLAN

- Dr Paul Wilson is the lead Infectious Disease Clinician responsible for the implementation of this CPG. He will form a small implementation team to consider necessary strategies for communication, audit and evaluation relating to the CPG. Respiratory Medicine, ED and ICU representation on the implementation group will occur.

- The small card form is issued to all JMOs and Registrars.

- ICUs implement the checklist for CAP cases (Appendix 2)

- EDs carry the CAP pathway which is made available on SALMAT (Appendix 1).

- GUIDANCE-DS at JHH will carry a computerised guideline algorithm for adult CAP that is consistent with this CPG.

4.0 EVALUATION PLAN

1. Individual patient review takes place during the weekly and twice weekly ICU liaison meetings conducted by Clinical Microbiology. Compliance with the CPG is promoted during these meetings

2. Annual Drug usage evaluation studies of CAP take place at Belmont, JHH, Mater & other sites with feedback to clinical groups. These DUE studies provide evidence of pathway compliance.

5.0 REFERENCES

Therapeutic Guidelines: Antibiotic, Therapeutic Guidelines, Edition 14, Melbourne, Victoria 2010


6.0 CONSULTATION LIST

- Infectious Diseases and Immunology, HAPS Microbiology
- Intensive Care and Emergency Departments
- Respiratory Medicine, JHH
- Area Quality Use of Medicines Committee
- Anti-microbial Working Group